English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduNonalcoholic steatohepatitis (NASH)-related cirrhosis can lead to serious liver-related outcomes. In a phase 2 trial, lead author Rohit Loomba, MD, University of California San Diego School of Medicine, and collaborators, report semaglutide 2.4 mg once weekly in patients with NASH-related cirrhosis…
Tag: Cirrhosis
Third Dose of COVID-19 Vaccine Offers Needed Boost in Protection for Cirrhosis Patients
New research led by researchers at the University of Miami Miller School of Medicine and published in the Journal of Hepatology, suggests that getting a third dose of the COVID-19 mRNA vaccine could overcome the decreased vaccine respons in cirrhosis patients and offer strong protection against the virus, severe illness, and death from COVID-19.
Smartphone App to Assess Stool Form, Rural-Urban Disparities in Cirrhosis Mortality, Lung Infection Risk in Severe Alcoholic Hepatitis in July Issue of AJG
The July issue of The American Journal of Gastroenterology highlights new clinical science including using a smartphone app to assess stool form, rural-urban disparities in cirrhosis mortality, and lung infection risk in severe alcohol-related hepatitis. This issue also includes articles on pediatric IBD, therapy options for Crohn’s disease, a novel endoscopic suturing device, proton pump inhibitors, and more.
COVID-19 Vaccine Protection Against Infection Lower and Slower in People with Liver Disease
A study shows for the first time that people with cirrhosis who receive mRNA COVID-19 vaccination gain important protection against more serious outcomes like hospitalization and death. At the same time, however, the vaccines offer less protection against SARS-CoV-2 infection and take longer to take effect in this population.
July Issue of The American Journal of Gastroenterology Includes Analysis of Psychological Comorbidities and Irritable Bowel Syndrome Prognosis
The July issue of AJG includes an examination of psychological comorbidities and the prognosis of individuals with IBS, as well as clinical research and reviews on cirrhosis, GERD, pediatrics, celiac disease, probiotics, GI quality improvement, NASH, and more.
January Issue of The American Journal of Gastroenterology Includes New Clinical Guideline on Irritable Bowel Syndrome
The January issue of The American Journal of Gastroenterology is now available and features new clinical research across a wide range of GI and hepatology topics, including NAFLD, colorectal cancer screening, GERD, post-COVID-19-associated functional GI disorder surges, celiac disease, and more.
December Issue of The American Journal of Gastroenterology Highlights Health Disparities and Social Determinants of Health
The December issue of The American Journal of Gastroenterology is now available and features new clinical research across a wide range of gastroenterology and hepatology topics, including health disparities, colorectal cancer, cirrhosis, pediatric gastroenterology, the environmental impact of endoscopy, and more.
Researchers Find County Differences in Liver Mortality in the U.S.
University of Miami Miller School of Medicine and Emory researchers found significant differences in death rates even within the same state, according to a recently published study in Gastroenterology.
Cirrhosis in North American Women on the Rise, Trend Especially Worrisome in Young Women
Data from a new study presented this week at The Liver Meeting Digital Experience® – held by the American Association for the Study of Liver Diseases – found that the burden of cirrhosis in women in North America has increased substantially in recent years, a worrying trend driven by a rise in alcohol-related liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD). Projections suggest that both ALD and NAFLD rates will result in even higher cirrhosis incidence by 2040, with the most worrisome upward trends seen in young women with ALD and post-menopausal women with NAFLD.
U.S. News & World Report: UC San Diego #1 for Gastroenterology and Hepatology Research
U.S. News & World Report named University of California San Diego School of Medicine a top global university and ranked the divisions of Gastroenterology and Hepatology #1 in the world for research.
Universal Gut Microbiome-Derived Signature Predicts Cirrhosis
UC San Diego School of Medicine researchers report that stool microbiomes of NAFLD patients are distinct enough to potentially be used to accurately predict which persons with NAFLD are at greatest risk for having cirrhosis.
Novel Antisense Drug Shows Promise in Slowing Fatty Liver Disease
A first-in-class clinical trial suggests a novel treatment measurably slowed progression of non-alcoholic fatty liver disease to its more progressive and deadly form.
Study: Two Enzymes Control Liver Damage in NASH
After identifying a molecular pathway that allows nonalcoholic steatohepatitis (NASH) to progress into liver cell death, University of California San Diego School of Medicine researchers were able to use these pathways to halt further liver damage.